Used in cancer research to target Frizzled-7 (FZD7) receptors involved in the Wnt signaling pathway. This antibody blocks aberrant Wnt activation, which is linked to tumor growth in cancers such as hepatocellular carcinoma, colorectal cancer, and triple-negative breast cancer. It serves as a research tool for studying tumor progression and stem cell regulation. Also explored for therapeutic development due to its ability to inhibit cancer cell proliferation and promote cell death in preclinical models. Supports immunoassays, flow cytometry, and immunohistochemistry to detect FZD7 expression in tissue samples.